MetLife Investment Advisors LLC reduced its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 36.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,581 shares of the specialty pharmaceutical company’s stock after selling 40,389 shares during the period. MetLife Investment Advisors LLC’s holdings in Antares Pharma were worth $189,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Antares Pharma during the 4th quarter valued at about $31,000. Foundations Investment Advisors LLC purchased a new position in Antares Pharma in the fourth quarter worth about $42,000. Virtu Financial LLC purchased a new position in Antares Pharma in the fourth quarter worth about $45,000. GSA Capital Partners LLP purchased a new position in Antares Pharma in the fourth quarter worth about $51,000. Finally, NewSquare Capital LLC raised its holdings in Antares Pharma by 33.8% in the fourth quarter. NewSquare Capital LLC now owns 21,611 shares of the specialty pharmaceutical company’s stock worth $59,000 after buying an additional 5,460 shares during the last quarter. 41.41% of the stock is owned by institutional investors.
Shares of ATRS stock opened at $2.72 on Monday. Antares Pharma Inc has a 52 week low of $2.16 and a 52 week high of $3.96. The company has a market capitalization of $436.65 million, a PE ratio of -68.00 and a beta of 1.11. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.62 and a quick ratio of 2.20.
Several research analysts have issued reports on the stock. BidaskClub cut shares of Antares Pharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 16th. TheStreet raised shares of Antares Pharma from a “d” rating to a “c” rating in a report on Friday, March 1st. Raymond James lifted their target price on shares of Antares Pharma from $5.25 to $5.65 and gave the stock a “strong-buy” rating in a report on Monday, March 4th. Finally, Cowen assumed coverage on shares of Antares Pharma in a report on Monday, February 25th. They issued an “outperform” rating and a $1.99 target price for the company. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $4.83.
In other news, Director Leonard S. Jacob sold 92,078 shares of Antares Pharma stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $3.00, for a total value of $276,234.00. Following the completion of the sale, the director now directly owns 301,970 shares in the company, valued at $905,910. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jacques Gonella sold 200,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $3.65, for a total transaction of $730,000.00. Following the completion of the sale, the director now owns 9,385,848 shares of the company’s stock, valued at $34,258,345.20. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.
Antares Pharma Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More: Call Option Volume
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.